Welcome to our dedicated page for NYSE news (Ticker: nyse), a resource for investors and traders seeking the latest updates and insights on NYSE stock.
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) is a clinical-stage biopharmaceutical company pioneering targeted radiotherapies for patients with advanced cancers. This news hub provides investors and healthcare professionals with timely updates on the company’s clinical developments, regulatory milestones, and strategic partnerships.
Access authoritative information about Actinium’s Antibody Radiation Conjugate (ARC) platform, including progress on lead candidates Iomab-B for bone marrow transplant conditioning and Iomab-ACT for CAR-T therapy preparation. Our curated news collection features press releases on trial results, FDA communications, and collaborations with leading cancer research centers.
Key updates include phase 3 trial data for hematologic malignancies, manufacturing advancements for radiotherapy agents, and scientific presentations at major oncology conferences. All content is vetted for accuracy and relevance to treatment innovation in cellular therapies.
Bookmark this page for streamlined tracking of Actinium’s progress in redefining cancer treatment paradigms through precision radiotherapy. Verify time-sensitive updates directly through SEC filings and official company communications.
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced positive results from the pivotal Phase 3 SIERRA trial of Iomab-B in relapsed/refractory acute myeloid leukemia (r/r AML) patients aged 55 and older, achieving a durable complete remission (dCR) rate of 75% (44/59 patients) and doubling overall survival at 1 year compared to the control arm. The company plans to submit a Biologics License Application (BLA) for Iomab-B in the second half of 2023 and is launching an Early Access Program. Actimab-A also demonstrated promising 1-year survival rates in a trial subset. With a strong financial position of $108.9 million, Actinium aims to fund operations through 2025.
Actinium Pharmaceuticals (NYSE: ATNM) announced the acceptance of two abstracts for presentation at the AACR 2023 Annual Meeting, scheduled for April 14-19, 2023, in Orlando, Florida. The abstracts focus on the novel application of Actimab-A to deplete immunosuppressive myeloid-derived suppressor cells (MDSCs) and the effectiveness of HER3-targeting radiotherapy in solid tumors, showcasing potent anti-cancer activity. Actinium's Chairman, Sandesh Seth, emphasized the company's commitment to advancing targeted radiotherapies to address significant medical needs, supported by their recent CRADA with the NCI for developing Actimab-A in various clinical trials.
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced its participation in Oppenheimer's 33rd Annual Healthcare Conference from March 13-17, 2023. The management team will present key updates, including the success of the pivotal Phase 3 SIERRA trial for Iomab-B, which achieved significant remissions in elderly patients with relapsed acute myeloid leukemia (AML). The Company has also signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to advance Actimab-A. The virtual presentation is scheduled for March 15, 2023, at 2:40 PM ET. More details can be found on Actinium's website.
On February 24, 2023, Hugoton Royalty Trust (HGTXU) announced the outcome of a special unitholder meeting held on February 23, 2023. Unitholders approved the appointment of Argent Trust Company as the successor trustee, contingent upon Simmons Bank's resignation. However, related amendments to the Trust's indenture did not receive enough votes for approval. The effective date for Simmons Bank's resignation depends on the fulfillment of certain conditions outlined in the trustee's notice. The press release also includes forward-looking statements that emphasize the uncertainty surrounding the transition and potential implications for the Trust's future operations.
Actinium Pharmaceuticals (NYSE: ATNM) reported positive survival data from its Actimab-A and CLAG-M combination trial for relapsed or refractory acute myeloid leukemia (AML) patients. Key findings include a 59% one-year overall survival for patients previously treated with Venetoclax, 75% measurable residual disease negativity, and a manageable safety profile. Notably, patients with a TP53 mutation showed a 52% one-year overall survival. These results were shared at the 64th Annual ASH Meeting, emphasizing the potential of Actimab-A as a treatment for high-risk AML patients previously deemed difficult to treat.
BARK, Inc. (NYSE: BARK) appointed Aarti Sharma as the new Chief People Officer, effective November 7, 2022. With 20 years in HR and people strategy, Sharma previously served as Global Head of HR at Cambium Networks, where she was key in its IPO. She aims to enhance BARK’s HR functions including talent acquisition and employee engagement. BARK, recognized as one of Newsweek’s Top 100 Most Loved Workplaces, continues to focus on employee satisfaction alongside its mission to bring joy to dogs. Sharma holds degrees in Statistics and an MBA.
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced positive results from its pivotal Phase 3 SIERRA trial of Iomab-B for treating elderly patients with active relapsed or refractory acute myeloid leukemia (AML). The trial met its primary endpoint, achieving a durable complete remission (dCR) of 6 months post-treatment, with a p-value of <0.0001. Iomab-B demonstrated significant potential to increase patient access to bone marrow transplants (BMT) and improve patient outcomes, prompting the company to advance its Biologics License Application (BLA) submission to the FDA.
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced a senior-level expansion of its clinical organization, strengthening its expertise in bone marrow transplant and acute myeloid leukemia. Key hires include Madhuri Vusirikala, MD, Akash Nahar, MD, Patrik Brodin, Ph.D., and Elaina Haeuber, enhancing the company's operational capabilities for pivotal programs Iomab-B and Actimab-A. Topline data from the Phase 3 SIERRA trial for Iomab-B is expected in Q4 2022. This expansion aims to advance clinical development and improve patient outcomes in hematological malignancies.
